Compare HCA Health Inc (HCA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Illumina, Inc. — how do they compare? HCA Health Inc trades at $448.9 (market cap $96.35B), while Illumina, Inc. trades at $270.7 (market cap $39.95B). The key difference: HCA Health Inc is far larger — about 2.4× Illumina, Inc.'s market cap, and HCA Health Inc pays a 0.7% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Illumina, Inc. for 83 Days on average.
| HCA | ILMN | |
|---|---|---|
Market Cap | $96.35B | $39.95B |
Volume | 1,079,453 | 3,169,503 |
Sector | Health | Health |
52-Week High | $545.13 | $293.69 |
52-Week Low | $361.32 | $91.00 |
Typical Hold Time | 76 Days | 83 Days |
Enterprise Value | $146.88B | $41.31B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
